LianBio Completes Phase 1 Pharmacokinetic Study of Mavacamten in Healthy Chinese Volunteers
May 09, 2022 08:00 ET
|
LianBio
Mavacamten demonstrated a favorable safety, tolerability and pharmacokinetic profile in healthy Chinese volunteers Study was conducted in parallel with ongoing Phase 3 EXPLORER-CN trial of mavacamten...
LianBio to Participate in the Bank of America Securities 2022 Healthcare Conference
May 05, 2022 16:05 ET
|
LianBio
SHANGHAI, China and PRINCETON, N.J., May 05, 2022 (GLOBE NEWSWIRE) -- LianBio (Nasdaq: LIAN), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major...
LianBio Partner Tarsus Pharmaceuticals Announces Positive Topline Data from Second Pivotal Trial of TP-03 for the Treatment of Demodex Blepharitis
May 03, 2022 08:00 ET
|
LianBio
SHANGHAI, China and PRINCETON, N.J., May 03, 2022 (GLOBE NEWSWIRE) -- LianBio’s (Nasdaq: LIAN) partner, Tarsus Pharmaceuticals, Inc. (Tarsus) yesterday announced that TP-03 (lotilaner ophthalmic...
U.S. Food and Drug Administration Approves Camzyos (mavacamten) for the Treatment of Adults with Symptomatic New York Heart Association Class II-III Obstructive Hypertrophic Cardiomyopathy (HCM) to Improve Functional Capacity and Symptoms
April 29, 2022 08:15 ET
|
LianBio
SHANGHAI and PRINCETON, N.J., April 29, 2022 (GLOBE NEWSWIRE) -- LianBio’s (Nasdaq: LIAN) partner, Bristol Myers Squibb, announced yesterday that the U.S. Food and Drug Administration (FDA) approved...
LianBio Announces Formation of Scientific Advisory Board
April 14, 2022 16:10 ET
|
LianBio
SHANGHAI, China and PRINCETON, N.J., April 14, 2022 (GLOBE NEWSWIRE) -- LianBio (Nasdaq: LIAN), a biotechnology company dedicated to bringing innovative medicines to patients in China and other...
LianBio’s Partner ReViral Enters into Acquisition Agreement with Pfizer
April 07, 2022 19:08 ET
|
LianBio
SHANGHAI AND PRINCETON, N.J., April 07, 2022 (GLOBE NEWSWIRE) -- LianBio (Nasdaq: LIAN) announced today that its partner, ReViral Ltd., is expected to be acquired by Pfizer Inc. (NYSE: PFE). LianBio...
LianBio Appoints Wei Wei Chen to Board of Directors
April 07, 2022 08:00 ET
|
LianBio
SHANGHAI and PRINCETON, N.J., April 07, 2022 (GLOBE NEWSWIRE) -- LianBio (Nasdaq: LIAN), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian...
LianBio Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
March 30, 2022 16:39 ET
|
LianBio
Phase 3 registrational trial of mavacamten in Chinese patients with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) ongoing Mavacamten granted breakthrough therapy designation in China for...
LianBio Issues Statement Regarding the HFCAA
March 10, 2022 18:12 ET
|
LianBio
SHANGHAI and PRINCETON, N.J., March 10, 2022 (GLOBE NEWSWIRE) -- Following the Determination Report of the Public Company Accounting Oversight Board (“PCAOB”) issued on December 16, 2021, on March...
LianBio Announces Mavacamten Granted Breakthrough Therapy Designation in China
February 15, 2022 07:00 ET
|
LianBio
SHANGHAI and PRINCETON, N.J., Feb. 15, 2022 (GLOBE NEWSWIRE) -- LianBio (Nasdaq: LIAN), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian...